Profile picture

Doctor Amit Khera

Verve Therapeutics, Boston (United States of America)
Follow
Logo ESC

Contributor content

Can gene editing address unmet need in dyslipidaemia?
Presentation
Can gene editing address unmet need in dyslipidaemia?
Read more
An investigational in vivo base editing medicine targeting ANGPTL3, VERVE-201, achieves potent and LDLR-independent liver editing in mouse models
Presentation
An investigational in vivo base editing medicine targeting ANGPTL3, VERVE-201, achieves potent and LDLR-independent liver editing in mouse models
Read more
An in vivo CRISPR base editing therapy to inactivate the ANGPTL3 gene: nomination of a development candidate for VERVE-201
Presentation
An in vivo CRISPR base editing therapy to inactivate the ANGPTL3 gene: nomination of a development candidate for VERVE-201
Read more

ESC 365 is supported by

novartis Explore sponsored resources